Montelukast Teva (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Teva is a leukotriene receptor antagonist used in the management of several respiratory and allergic conditions.

Asthma: provides maintenance therapy that reduces the frequency and severity of asthma symptoms. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity. Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea associated with seasonal or perennial allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness - Fatigue - Cough

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Severe rash or Stevens‑Johnson syndrome - Hepatic injury - Mood changes, including suicidal thoughts

Montelukast should be used with awareness of specific safety considerations.

Pregnancy: safety category is unknown; use only if the potential benefit justifies the risk. Breastfeeding: unknown excretion in milk; weigh benefits against possible risks. Liver impairment: dose adjustment may be required; monitor hepatic function. Age restrictions: not recommended for children under 12 years for asthma maintenance therapy. Drug interactions: review concomitant medications for potential interactions. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: may markedly reduce montelukast plasma concentrations. - Ketoconazole or other potent CYP3A4 inhibitors: may increase montelukast exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Concurrent use with other leukotriene pathway inhibitors (e.g., zafirlukast): may increase risk of liver enzyme abnormalities. - Phenobarbital: may modestly lower montelukast levels. - Antidepressants (e.g., fluoxetine): monitor for neuropsychiatric symptoms.